A Draft Guidance for Industry about Medication Guides and REMS has been published for comment purposes (February 2011); the draft Guidance indicates that it is intended to address 2 topics pertaining to Medication Guides for drug and biological products-that...
Posted by Joan Shipman on April 6, 2011 3:05 PM
Sept 5, 2008 FDA announced (1) that it has posted on its Web site its first quarterly report that lists certain drugs that are being evaluated for potential safety issues.(2) The drugs have been identified based on a review of...
Posted by Joan Shipman on September 6, 2008 4:33 PM
Today's FDA webpage show key initatives in their 'Spotlight' focus. This provides a nice overview of what is happening here in recent history and links to the respective website that focuses on each initiative. Through specially targeted initiatives, FDA intensifies...
Posted by Joan Shipman on August 2, 2008 3:52 PM
For purposes of thinking about trends, I found it interesting to take a look at the last 6 months of FDA/CDER Warning Letters resulting from inspections in regard to its Bioresearch Monitoring Program. The Warning Letters show recent and...
Posted by Joan Shipman on July 10, 2008 6:50 AM
For stargazers who visit Supra, here is a weekly publication I have found useful over time--it is grounded in business. The 'Business Digest' newsletter from the Pharmaceutical Business Review (1) published weekly, originates in the UK. With due respect to...
Posted by Joan Shipman on July 9, 2008 7:17 AM
May 22, 2008, HHS Secretary Mike Leavitt announced new FDA/CMS efforts that will complement each other to improve patient safety and the quality of medical care.(1) Read more about the big picture and how CBO sees the Federal government's Activities...
Posted by Joan Shipman on May 23, 2008 7:32 AM
The U.S. House of Representatives, Committee on Oversight and Government Reform held a hearing titled, “Should FDA Drug and Medical Device Regulation Bar State Liability Claims?” on Wednesday, May 14, 2008.(1)Chairman Waxman's Opening Statement states in part: FDA approval of...
Posted by Joan Shipman on May 20, 2008 11:26 AM
From the State Bar News, NYSBA's Annual Meeting Edition (March/April 2008), an article by Cailin Brown on the Presidential Summit, am panel, leads the issue (1) ...Experts shared ideas on breaking the cycle for youth at risk, Cailin Brown reports,...
Posted by Joan Shipman on April 15, 2008 7:18 AM
Just out: FDA's "Prescription Drug User Fee Act (PDUFA) IV Drug Safety Five-Year Plan" draft document dated March 2008.(1) FDA will use this plan to communicate strategies FDA will follow for using PDUFA IV drug safety resources; communicate our current...
Posted by Joan Shipman on April 2, 2008 8:42 AM
From CDER's email news of today: FDA provides Q&A on the Federal Register Notice on Drugs and Biological Products Deemed to Have A Risk Evaluation and Mitigation Strategy ("REMS"). (1) [re: 3/27/08 Federal Register Notice see (2)] FDA is: identifying...
Posted by Joan Shipman on March 27, 2008 1:52 PM
Zooming in to focus on particular sections of the FDA Amendments Act of 2007, I first took note of Section 1103 of the FDAAA, “improving genetic test safety and quality,” which requires that by July 2008 the Secretary’s Advisory Committee...
Posted by Joan Shipman on October 30, 2007 12:17 PM
If you use an RSS reader, you can subscribe to a feed of all future entries tagged 'FDAAA'. [What is this?]
Other tags used on this blog: